PAH Clinical Trial Designs Are Evolving, Paving the Way Toward Improved Therapies

Author: Maureen Newman
Date Published: September-2015
Source: Pulmonary Hypertension News

The recent announcement of positive results for the AMBITION trial testing combinatorial ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH) is bringing more attention to the need to actively recruit participants for clinical trials. Without patients and clinicians interested in trying new treatments for a currently incurable condition, promising new therapies cannot be brought to market for the general PAH population.